CRISPR Therapeutics AG financial data

Symbol
CRSP on Nasdaq
Location
Zug
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 10 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1734% % -3.2%
Debt-to-equity 18% % 0.34%
Return On Equity -26% % -118%
Return On Assets -22% % -117%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 95,300,233 shares 12%
Common Stock, Shares, Outstanding 93,872,794 shares 10%
Entity Public Float $4,300,000,000 USD 4.9%
Common Stock, Value, Issued $3,013,000 USD 12%
Weighted Average Number of Shares Outstanding, Basic 91,305,337 shares 7.1%
Weighted Average Number of Shares Outstanding, Diluted 91,305,337 shares 7.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $38,337,000 USD -81%
Research and Development Expense $283,436,000 USD -15%
General and Administrative Expense $73,267,000 USD 2.7%
Operating Income (Loss) $574,396,000 USD -73%
Nonoperating Income (Expense) $89,819,000 USD -6.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $484,577,000 USD -105%
Income Tax Expense (Benefit) $3,720,000 USD 19%
Net Income (Loss) Attributable to Parent $488,297,000 USD -104%
Earnings Per Share, Basic -5 USD/shares -98%
Earnings Per Share, Diluted -5 USD/shares -98%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $286,497,000 USD 27%
Marketable Securities, Current $1,629,213,000 USD -4.7%
Accounts Receivable, after Allowance for Credit Loss, Current $0 USD
Assets, Current $1,929,092,000 USD -0.76%
Property, Plant and Equipment, Net $120,831,000 USD -13%
Operating Lease, Right-of-Use Asset $134,659,000 USD -7.9%
Other Assets, Noncurrent $24,308,000 USD 53%
Assets $2,245,308,000 USD -0.48%
Accounts Payable, Current $11,798,000 USD -24%
Employee-related Liabilities, Current $10,154,000 USD -33%
Accrued Liabilities, Current $84,182,000 USD 78%
Contract with Customer, Liability, Current $1,295,000 USD -71%
Liabilities, Current $118,957,000 USD 32%
Contract with Customer, Liability, Noncurrent $12,323,000 USD 0%
Operating Lease, Liability, Noncurrent $192,768,000 USD -8.5%
Other Liabilities, Noncurrent $5,278,000 USD 44%
Liabilities $329,326,000 USD 4.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax $4,986,000 USD -53%
Retained Earnings (Accumulated Deficit) $1,816,938,000 USD -37%
Stockholders' Equity Attributable to Parent $1,915,982,000 USD -1.2%
Liabilities and Equity $2,245,308,000 USD -0.48%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $53,947,000 USD -149%
Net Cash Provided by (Used in) Financing Activities $10,588,000 USD -97%
Net Cash Provided by (Used in) Investing Activities $19,755,000 USD 80%
Common Stock, Shares Authorized 132,477,166 shares 0%
Common Stock, Shares, Issued 93,998,110 shares 9.9%
Common Stock, Par or Stated Value Per Share 0.03 CHF/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $63,073,000 USD -120%
Deferred Tax Assets, Valuation Allowance $282,739,000 USD 24%
Deferred Tax Assets, Gross $355,484,000 USD 15%
Operating Lease, Liability $223,693,000 USD -6.3%
Depreciation $18,500,000 USD -4.1%
Payments to Acquire Property, Plant, and Equipment $206,000 USD -71%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $493,876,000 USD -122%
Lessee, Operating Lease, Liability, to be Paid $294,630,000 USD -8.7%
Property, Plant and Equipment, Gross $206,444,000 USD 0.05%
Operating Lease, Liability, Current $18,256,000 USD 8.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two $29,468,000 USD 2.2%
Lessee, Operating Lease, Liability, to be Paid, Year One $29,416,000 USD 2.5%
Operating Lease, Weighted Average Discount Rate, Percent 0.06 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $70,937,000 USD -16%
Lessee, Operating Lease, Liability, to be Paid, Year Three $28,704,000 USD -2.4%
Deferred Tax Assets, Operating Loss Carryforwards $178,061,000 USD 33%
Unrecognized Tax Benefits $49,959,000 USD 13%
Lessee, Operating Lease, Liability, to be Paid, Year Four $28,158,000 USD -1.8%
Depreciation, Depletion and Amortization $4,736,000 USD -2%
Deferred Tax Assets, Net of Valuation Allowance $72,745,000 USD -9.3%
Share-based Payment Arrangement, Expense $76,370,000 USD -8%